Group 1 - The company, Akeso Inc. (09939), experienced a significant decline of over 14%, trading at HKD 2.2 with a transaction volume of HKD 53.6885 million [1] - Akeso announced a placement of 20.673 million shares at a price of HKD 2.08 per share, representing an 18.75% discount from the previous closing price of HKD 2.56, with estimated net proceeds of approximately HKD 40.34 million [1] - The net proceeds from the placement will be used for general working capital and business purposes, resulting in a reduction of the shareholding of the company's co-founder and major shareholder, Tong Youzhi, from 11.19% to 10.69% [1] Group 2 - The company has completed the enrollment of 666 patients in the critical Phase III clinical trial for its self-developed potential first-in-class KX-826 topical solution for hair loss [1] - The Phase II portion of the trial has met its primary endpoint with statistically significant and clinically meaningful results, demonstrating both efficacy and safety [1] - The company cannot ensure the successful development and eventual commercialization of KX-826 or other products beyond the KX-826 topical solution and acne cream [1]
港股异动 开拓药业-B(09939)重挫逾14% 公司拟折让18.75%配售股份 净筹约4034万港元